News|Articles|September 3, 2025

ESC Congress 2025 Recap: 8 Trials to Know

A recap 8 clinical trials in cardiovascular care to know from the European Society of Cardiology Congress 2025.

Europe’s biggest stage for cardiovascular science once again delivered headline-making results in 2025. This year’s European Society of Cardiology (ESC) Congress showcased trials spanning the spectrum of cardiovascular subspecialties—from heart failure and hypertrophic cardiomyopathy to hypertension, lipid management, and triglyceride lowering. While some studies reinforced momentum for established therapies, others raised new questions or pointed toward emerging options that could reshape care.

Related to this article

September 22nd, 2026

FDA Updates Sotatercept Label with HYPERION Data in Early PAH

The FDA-approved update adds phase 3 HYPERION data on adults diagnosed with PAH within the past year.

September 24th, 2026

Q&A: Clinician Investing and Injection Anxiety, With Manju Dawkins, MD

Manju Dawkins, MD, discusses Skin Angels, why clinicians belong in dermatology innovation, and her work to reduce injection pain and needle anxiety.

September 23rd, 2026

Conference Preview: 2026 EADV Congress in Vienna

This preview of EADV 2026 provides a teaser of new data and interviews being highlighted at this Vienna dermatology conference.

September 21st, 2026

PAH Experts Discuss Trial-to-Clinic Mismatch in Care

Philadelphia-area PAH specialists discuss real-world patient mismatch with trial criteria, drug sequencing, and insurance access barriers.

September 26th, 2026

Hereditary Angioedema Triggers, Prodromes Mapped in US HAEA Registry

Stress led all triggers, and a sense of an impending attack was the most reliable prodrome in patients with HAE-C1INH in the US HAEA Scientific Registry.

September 26th, 2026

The HCPFive: Top News for Healthcare Providers from the Week of 09/20

Stay updated with the latest healthcare breakthroughs, including the FDA approval of insulin efsitora alfa-gobe (Onswik).

September 25th, 2026

FDA Approves Baricitinib for Adolescents With Severe Alopecia Areata

Approval is based on 36-week data from BRAVE-AA-PEDS, in which 42% of patients on the 4 mg dose achieved a SALT score of 20 or less, compared with 5% on placebo.

Image Credit: US Food and Drug Administration

September 25th, 2026

Zilurgisertib Receives FDA Approval for FOP in Patients 12 and Older

The FDA approved once-daily oral zilurgisertib for FOP in patients aged 12 years and older after the phase 2 PROGRESS trial showed reduced new heterotopic ossification vs placebo.